Cargando…

Comparative Efficacy (DAS28 Remission) of Targeted Immune Modulators for Rheumatoid Arthritis: A Network Meta-Analysis

INTRODUCTION: The objective of this study was to evaluate the relative efficacy of targeted immune modulators (TIMs) in TIM-naïve/mixed populations (≤ 20% TIM-experienced) and TIM-experienced (> 20% TIM-experienced) adults with moderate-to-severe rheumatoid arthritis with an inadequate response t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Best, Jennie H., Kuang, Yuting, Jiang, Yilin, Singh, Rajpal, Karabis, Andreas, Uyei, Jennifer, Dang, Joseph, Reiss, William G.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8217484/ https://www.ncbi.nlm.nih.gov/pubmed/34037968 http://dx.doi.org/10.1007/s40744-021-00322-y

Ejemplares similares

DAS28‐CRP Cutoffs for High Disease Activity and Remission Are Lower Than DAS28‐ESR in Rheumatoid Arthritis
por: Greenmyer, Jacob R., et al.
Publicado: (2020)

Pain persists in DAS28 rheumatoid arthritis remission but not in ACR/EULAR remission: a longitudinal observational study
por: Lee, Yvonne C, et al.
Publicado: (2011)

Response to 'Pain persists in DAS28 rheumatoid arthritis remission but not in ACR/EULAR remission: a longitudinal observational study'
por: Yoshida, Kazuki, et al.
Publicado: (2011)

Silent progression in patients with rheumatoid arthritis: is DAS28 remission an insufficient goal in RA? Results from the German Remission-plus cohort
por: Sewerin, Philipp, et al.
Publicado: (2017)

DAS28-CRP and DAS28-ESR cut-offs for high disease activity in rheumatoid arthritis are not interchangeable
por: Fleischmann, Roy M, et al.
Publicado: (2017)

Discrepancies in assessment of patients with rheumatoid arthritis and secondary Sjögren's syndrome by DAS28-ESR and DAS28-CRP
por: Romanowska-Próchnicka, Katarzyna, et al.
Publicado: (2016)

Gender stratified adjustment of the DAS28-CRP improves inter-score agreement with the DAS28-ESR in rheumatoid arthritis
por: Hamann, Philip D H, et al.
Publicado: (2019)

Use of rheumatoid arthritis impact of disease (RAID) in routine care; identification of DAS28 remission and unmet patient-reported outcomes
por: Mistry, Jatin, et al.
Publicado: (2020)

Evaluation of newly proposed remission cut-points for disease activity score in 28 joints (DAS28) in rheumatoid arthritis patients upon IL-6 pathway inhibition
por: Schoels, M., et al.
Publicado: (2017)

The association of anti-CCP1 antibodies with disease activity score 28 (DAS-28) in rheumatoid arthritis
por: Karimifar, Mansoor, et al.
Publicado: (2012)

DAS28: a useful instrument to monitor infliximab treatment in patients with rheumatoid arthritis
por: van Riel, Piet LCM, et al.
Publicado: (2005)

Serum 14-3-3η level is associated with severity and clinical outcomes of rheumatoid arthritis, and its pretreatment level is predictive of DAS28 remission with tocilizumab
por: Hirata, Shintaro, et al.
Publicado: (2015)

The validity of a rheumatoid arthritis medical records-based index of severity compared with the DAS28
por: Sato, Masayo, et al.
Publicado: (2006)

The validity of a rheumatoid arthritis medical records-based index of severity compared with the DAS28
por: Landewé, Robert, et al.
Publicado: (2006)

The Utility and Limitations of CRP, ESR and DAS28-CRP in Appraising Disease Activity in Rheumatoid Arthritis
por: Orr, Carl K., et al.
Publicado: (2018)

Interpretation of DAS28 and its components in the assessment of inflammatory and non-inflammatory aspects of rheumatoid arthritis
por: McWilliams, Daniel F., et al.
Publicado: (2018)

DAS28 best reflects the physician's clinical judgment of response to infliximab therapy in rheumatoid arthritis patients: validation of the DAS28 score in patients under infliximab treatment
por: Vander Cruyssen, Bert, et al.
Publicado: (2005)

Remission in Rheumatoid Arthritis
por: Shammas, Rania M., et al.
Publicado: (2010)

Using a DAS28-CRP-steered treat-to-target strategy does not eliminate subclinical inflammation as assessed by ultrasonography in rheumatoid arthritis patients in longstanding clinical remission
por: Terslev, Lene, et al.
Publicado: (2021)

A systematic comparison of different composite measures (DAS 28, CDAI, SDAI, and Boolean approach) for determining treatment effects on low disease activity and remission in rheumatoid arthritis
por: Janke, Kirsten, et al.
Publicado: (2022)

Comparison between low disease activity or DAS remission as treatment target in patients with early active rheumatoid arthritis
por: Akdemir, Gülşah, et al.
Publicado: (2018)

Reliability and validity of CDAI and SDAI indices in comparison to DAS-28 index in Moroccan patients with rheumatoid arthritis
por: Slama, Imane Ben, et al.
Publicado: (2015)

Baseline bony erosions and time-averaged DAS28 predict discontinuation of TNF inhibitors in rheumatoid arthritis
por: Min, Hong Ki, et al.
Publicado: (2022)

Predictors of European League Against Rheumatism (EULAR) good response, DAS-28 remission and sustained responses to TNF-inhibitors in rheumatoid arthritis: a prospective study in refractory disease
por: Mohammed, Reem Hamdy A, et al.
Publicado: (2015)

Early DAS response after DMARD-start increases probability of achieving sustained DMARD-free remission in rheumatoid arthritis
por: Verstappen, M., et al.
Publicado: (2020)

DAS-28-based EULAR response and HAQ improvement in rheumatoid arthritis patients switching between TNF antagonists
por: Navarro-Sarabia, Federico, et al.
Publicado: (2009)

Durability of Response to Tocilizumab Therapy in Rheumatoid Arthritis: Data from the US-Based Corrona Rheumatoid Arthritis Registry
por: Pappas, Dimitrios A., et al.
Publicado: (2021)

Ultrasound remission in patients with rheumatoid arthritis in clinical remission
por: Fakhfakh, Rym, et al.
Publicado: (2021)

IL-18 correlates positively with CRP and IL-1Ra but not with DAS28 or bone erosion in patients with rheumatoid arthritis
por: Nielsen, H, et al.
Publicado: (2002)

DAS28 score vs. ultrasound examination for assessment of rheumatoid arthritis disease activity: comparison and discussion of pros and cons
por: Barczyńska, Tacjana Anna, et al.
Publicado: (2015)

Optimal responses in disease activity scores to treatment in rheumatoid arthritis: Is a DAS28 reduction of >1.2 sufficient?
por: Mian, Aneela N., et al.
Publicado: (2016)

The DAS28-ESR cutoff value necessary to achieve remission under the new Boolean-based remission criteria in patients receiving tocilizumab
por: Hirabayashi, Yasuhiko, et al.
Publicado: (2012)

CRP genotype and haplotype associations with serum C-reactive protein level and DAS28 in untreated early rheumatoid arthritis patients
por: Ammitzbøll, Christian Gytz, et al.
Publicado: (2014)

Validation of the 28-joint Disease Activity Score (DAS28) and European League Against Rheumatism response criteria based on C-reactive protein against disease progression in patients with rheumatoid arthritis, and comparison with the DAS28 based on erythrocyte sedimentation rate
por: Wells, G, et al.
Publicado: (2008)

Ultrasound-detected subclinical inflammation was better reflected by the disease activity score (DAS-28) in patients with suspicion of inflammatory arthritis compared to established rheumatoid arthritis
por: Ciurtin, Coziana, et al.
Publicado: (2016)

Validity of Remission Criteria in Rheumatoid Arthritis Compared to Ultrasound-Defined Remission
por: Ben Abdelghani, Kawther, et al.
Publicado: (2022)

Patient’s perspective of sustained remission in rheumatoid arthritis
por: Contreras-Yáñez, Irazú, et al.
Publicado: (2017)

Prevalence and predictors for sustained remission in rheumatoid arthritis
por: Sung, Yoon-Kyoung, et al.
Publicado: (2019)

The Economic Benefit of Remission for Patients with Rheumatoid Arthritis
por: Curtis, Jeffrey R., et al.
Publicado: (2022)

Role of ultrasonography in diagnosing early rheumatoid arthritis and remission of rheumatoid arthritis - a systematic review of the literature
por: Ten Cate, David F, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_7n8cue0vf850ve7oqidms7t06n